Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company’s development project NVP014 for the treatment of ischemic stroke is entering a new phase in collaboration with UK partner Isomerase Therapeutics. The former collaboration with to-BBB of the Netherlands concluded at the end of 2014 and on the basis of the results obtained, NeuroVive is now developing new molecules and a more effective method for penetrating the blood-brain barrier.NeuroVive’s collaboration with to-BBB Technologies B.V. of the Netherlands on the development of NVP014 for